BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

453 related articles for article (PubMed ID: 27744334)

  • 1. Shape matters: the complex relationship between aggregation and toxicity in protein-misfolding diseases.
    Ries HM; Nussbaum-Krammer C
    Essays Biochem; 2016 Oct; 60(2):181-190. PubMed ID: 27744334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The spread of prion-like proteins by lysosomes and tunneling nanotubes: Implications for neurodegenerative diseases.
    Victoria GS; Zurzolo C
    J Cell Biol; 2017 Sep; 216(9):2633-2644. PubMed ID: 28724527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protein Misfolding Diseases.
    Hartl FU
    Annu Rev Biochem; 2017 Jun; 86():21-26. PubMed ID: 28441058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prions and the potential transmissibility of protein misfolding diseases.
    Kraus A; Groveman BR; Caughey B
    Annu Rev Microbiol; 2013; 67():543-64. PubMed ID: 23808331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prion-Like Protein Aggregates and Type 2 Diabetes.
    Mukherjee A; Soto C
    Cold Spring Harb Perspect Med; 2017 May; 7(5):. PubMed ID: 28159831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of Pairs of Toxic and Nontoxic Misfolded Protein Oligomers Elucidates the Structural Determinants of Oligomer Toxicity in Protein Misfolding Diseases.
    Limbocker R; Cremades N; Cascella R; Tessier PM; Vendruscolo M; Chiti F
    Acc Chem Res; 2023 Jun; 56(12):1395-1405. PubMed ID: 37071750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. From Seeds to Fibrils and Back: Fragmentation as an Overlooked Step in the Propagation of Prions and Prion-Like Proteins.
    Marrero-Winkens C; Sankaran C; Schätzl HM
    Biomolecules; 2020 Sep; 10(9):. PubMed ID: 32927676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Animal models for prion-like diseases.
    Fernández-Borges N; Eraña H; Venegas V; Elezgarai SR; Harrathi C; Castilla J
    Virus Res; 2015 Sep; 207():5-24. PubMed ID: 25907990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prion-like features of misfolded Aβ and tau aggregates.
    Morales R; Callegari K; Soto C
    Virus Res; 2015 Sep; 207():106-12. PubMed ID: 25575736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanistic Insights into the Role of Molecular Chaperones in Protein Misfolding Diseases: From Molecular Recognition to Amyloid Disassembly.
    Hervás R; Oroz J
    Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33276458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathogenic mechanisms of prion protein, amyloid-β and α-synuclein misfolding: the prion concept and neurotoxicity of protein oligomers.
    Ugalde CL; Finkelstein DI; Lawson VA; Hill AF
    J Neurochem; 2016 Oct; 139(2):162-180. PubMed ID: 27529376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Misfolded protein aggregates: mechanisms, structures and potential for disease transmission.
    Moreno-Gonzalez I; Soto C
    Semin Cell Dev Biol; 2011 Jul; 22(5):482-7. PubMed ID: 21571086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent progress in prion and prion-like protein aggregation.
    Yi CW; Xu WC; Chen J; Liang Y
    Acta Biochim Biophys Sin (Shanghai); 2013 Jun; 45(6):520-6. PubMed ID: 23709368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Type 2 diabetes as a protein misfolding disease.
    Mukherjee A; Morales-Scheihing D; Butler PC; Soto C
    Trends Mol Med; 2015 Jul; 21(7):439-49. PubMed ID: 25998900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Underlying mechanisms and chemical/biochemical therapeutic approaches to ameliorate protein misfolding neurodegenerative diseases.
    Hekmatimoghaddam S; Zare-Khormizi MR; Pourrajab F
    Biofactors; 2017 Nov; 43(6):737-759. PubMed ID: 26899445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Camelid single-domain antibody fragments: Uses and prospects to investigate protein misfolding and aggregation, and to treat diseases associated with these phenomena.
    Pain C; Dumont J; Dumoulin M
    Biochimie; 2015 Apr; 111():82-106. PubMed ID: 25656912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Review: membrane-associated misfolded protein propagation in natural transmissible spongiform encephalopathies (TSEs), synthetic prion diseases and Alzheimer's disease.
    Jeffrey M
    Neuropathol Appl Neurobiol; 2013 Apr; 39(3):196-216. PubMed ID: 23171056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibiting toxic aggregation of amyloidogenic proteins: a therapeutic strategy for protein misfolding diseases.
    Cheng B; Gong H; Xiao H; Petersen RB; Zheng L; Huang K
    Biochim Biophys Acta; 2013 Oct; 1830(10):4860-71. PubMed ID: 23820032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Can prion-like propagation occur in neurodegenerative diseases?: in view of transmissible systemic amyloidosis].
    Yoshida K; Higuchi K; Ikeda S
    Brain Nerve; 2012 Jun; 64(6):665-74. PubMed ID: 22647474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteomic analysis of protein homeostasis and aggregation.
    Laskowska E; Kuczyńska-Wiśnik D; Lipińska B
    J Proteomics; 2019 Apr; 198():98-112. PubMed ID: 30529741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.